Biodesix, Inc. (NASDAQ:BDSX) Chairman John Patience Acquires 279,329 Shares

Biodesix, Inc. (NASDAQ:BDSXGet Rating) Chairman John Patience bought 279,329 shares of the stock in a transaction on Thursday, April 7th. The stock was purchased at an average cost of $1.79 per share, with a total value of $499,998.91. Following the acquisition, the chairman now owns 337,926 shares in the company, valued at $604,887.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of BDSX opened at $1.66 on Thursday. Biodesix, Inc. has a 1 year low of $1.56 and a 1 year high of $19.75. The business has a 50-day moving average of $2.41 and a 200-day moving average of $4.77.

Biodesix (NASDAQ:BDSXGet Rating) last issued its quarterly earnings data on Monday, March 14th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.49). During the same period in the prior year, the company earned ($0.25) EPS. On average, research analysts anticipate that Biodesix, Inc. will post -1.13 EPS for the current fiscal year.

Several equities analysts have commented on BDSX shares. Zacks Investment Research downgraded Biodesix from a “buy” rating to a “hold” rating in a research report on Thursday, March 17th. Canaccord Genuity Group dropped their target price on Biodesix from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, February 15th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from, the stock currently has an average rating of “Buy” and a consensus price target of $15.35.

Institutional investors have recently made changes to their positions in the stock. Morgan Stanley increased its holdings in Biodesix by 148.9% in the third quarter. Morgan Stanley now owns 108,523 shares of the company’s stock worth $892,000 after purchasing an additional 64,919 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Biodesix during the 4th quarter worth approximately $275,000. Two Sigma Investments LP bought a new stake in shares of Biodesix in the 3rd quarter valued at $321,000. Chicago Capital LLC bought a new stake in shares of Biodesix in the 4th quarter valued at $143,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Biodesix during the 3rd quarter valued at $156,000. Institutional investors own 75.82% of the company’s stock.

Biodesix Company Profile (Get Rating)

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

See Also

Insider Buying and Selling by Quarter for Biodesix (NASDAQ:BDSX)

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with's FREE daily email newsletter.